- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Facing pharmacy trends for the remainder of the year
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- State of the market: Are generic drugs approaching their peak?
- Americans more likely than others to prefer generics, study finds
JERUSALEM — A generic drug maker has launched its version of an Abbott Labs drug.
Teva Pharmaceutical Industries said it launched progesterone capsules in the 100-mg and 200-mg strengths, a generic version of Prometrium.
Prometrium is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug also is indicated for use in secondary amenorrhea.
For the 12 months ended Jan. 31, Prometrium had sales of approximately $198 million, according to IMS Health data.